Due to a high load of modelling projects, the rate of submission via the website has been reduced.
For a much higher submission rate, please use the Modelling API.

Q69FE3 (Q69FE3_HUMAN) Homo sapiens (Human)

Interleukin-1 receptor-associated kinase 4 UniProtKBInterProInteractive Modelling

460 aa; Sequence (Fasta) ; 1 identical sequence: Homo sapiens: Q9NWZ3

Available Structures

72 Experimental Structures

DescriptionPDB IDOligo-stateRangeLigands
The ternary Death Domain complex of MyD88, IRAK4, and IRAK2 Heteromer
O43187; Q99836; Q9NWZ3;
4-106
Assess
Crystal Structure of IRAK4 kinase in complex with the inhibitor CA-4948homo-4-mer162-460
FJ0;
Assess
Crystal structure of Compound 19 bound to IRAK4homo-4-mer162-458
QL7;SO4;
Assess
CRYSTAL STRUCTURE OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 (IRAK4-WT) COMPLEX WITH A NICOTINAM…homo-4-mer162-458
R7S; 10×SO4;
Assess
Crystal Structure of IRAK4 kinase in complex with a small molecule inhibitorhomo-4-mer163-458
FJ9;
Assess
Crystal structure of the unphosphorylated IRAK4 kinase domain Bound to a type I inhibitorhomo-2-mer164-459
DL1;
Assess
IRAK4 in complex with Ponatinibhomo-2-mer164-459
0LI;SO4;CO;
Assess
IRAK4 in complex with a type II inhibitorhomo-2-mer164-459
J8A;SO4;CO;
Assess
Crystal structure of the unphosphorylated IRAK4 kinase domain Bound to a type I inhibitorhomo-2-mer164-458
J87;
Assess
Crystal Structure of Asymmetric IRAK4 Dimerhomo-2-mer166-458
STU;SO4;
Assess
Sulphur Anomalous Crystal Structure of Asymmetric IRAK4 Dimerhomo-2-mer166-458
STU;SO4;
Assess
Structure of the IRAK4 kinase domain with compound 41monomer162-459
SO4;LSV;
Assess
Irak4-inhibitor co-structuremonomer162-459
4S2;
Assess
Crystal structure of IRAK4 in complex with compound 14monomer162-458
8CD;
Assess
Crystal structure of IRAK4 kinase domain apo formmonomer162-458
Assess
Crystal structure of human Interleukin-1 receptor associated Kinase 4 (IRAK 4, CID 100300) in compl…monomer164-460
JX4;
Assess
Crystal structure of IRAK4 kinase domain with inhibitormonomer163-459
XPY;
Assess
Irak4-inhibitor co-structuremonomer163-459
4S3;
Assess
Irak4 kinase - compound 1 co-structuremonomer163-459
76Q;
Assess
Irak4-inhibitor co-structuremonomer163-459
4GD;
Assess
Irak4 kinase - compound 1 co-structuremonomer163-459
76P;
Assess
Structure of the IRAK4 kinase domain with compound 5monomer162-458
LTY;
Assess
IRAK4 IN COMPLEX WITH inhibitormonomer163-459
ND2;
Assess
Crystal structure of the inactive unphosphorylated IRAK4 kinase domain bound to AMP-PNPmonomer164-460
ANP;SO4;MG;
Assess
Irak4-inhibitor co-structuremonomer163-459
6YE;
Assess
Discovery of IRAK4 Inhibitor 41monomer163-459
R73;
Assess
Irak4-inhibitor co-structuremonomer163-459
42P;
Assess
Structure of the IRAK4 kinase domain with compound 17monomer163-458
CA;LRS;
Assess
IRAK4 bound to benzoxazole compoundmonomer164-459
KFD;
Assess
IRAK4 in complex with inhibitormonomer163-458
EXF;
Assess
Crystal structure of IRAK4 kinase domain complexed with staurosporinemonomer163-458
STU;
Assess
Crystal structure of IRAK4 in complex with compound 9monomer164-459
8BV;
Assess
Irak4-inhibitor co-structuremonomer164-459
4GF;
Assess
Crystal structure of IRAK4 in complex with compound 23monomer164-458
LS7;SO4;GOL;
Assess
IRAK4 in complex with inhibitormonomer164-458
N9Z;
Assess
Crystal structure of IRAK-4monomer164-458
SO4;T12;
Assess
IRAK4 in complex with Compound 1monomer164-458
6QX;
Assess
IRAK4 in complex with inhibitormonomer164-458
B4U;
Assess
Crystal structure of IRAK-4monomer164-458
STU;
Assess
Discovery of IRAK4 Inhibitor 40monomer165-459
R6I;
Assess
Discovery of IRAK4 Inhibitor 38monomer165-459
O06;
Assess
IRAK4 in complex with Compound 21monomer164-458
SO4;6QY;
Assess
IRAK4 in complex with AZ3862monomer164-458
SO4;6R0;
Assess
CRYSTAL STRUCTURE OF IRAK-4 WITH A 4,6-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 9)monomer164-458
9YS;
Assess
Crystal structure of IRAK4 kinase domain complexed with AMPPNPmonomer164-458
ANP;
Assess
IRAK4 in complex with AZ3864monomer164-458
6QZ;
Assess
IRAK4 IN COMPLEX WITH inhibitormonomer165-459
NBW;
Assess
Discovery of IRAK4 Inhibitor 16monomer165-459
O0H;GOL;
Assess
IRAK4 IN COMPLEX WITH inhibitormonomer164-458
CJN;
Assess
IRAK4 IN COMPLEX WITH inhibitormonomer164-458
SO4;CJT;
Assess
Irak4-inhibitor co-structuremonomer165-459
4S1;
Assess
Apo IRAK4 Kinase Domainmonomer165-459
Assess
IRAK4 in complex with inhibitormonomer164-458
NBK;
Assess
IRAK4 IN COMPLEX WITH COMPOUND #3monomer165-459
SO9;BME;
Assess
Discovery of IRAK4 Inhibitor 23monomer165-459
O6X;
Assess
IRAK4 IN COMPLEX WITH inhibitormonomer164-458
SO4;CJQ;
Assess
CRYSTAL STRUCTURE OF IRAK-4 WITH A 4,6-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 4)monomer165-459
9YY;
Assess
IRAK4 in complex with inhibitormonomer164-458
B6I;
Assess
The Crystal Structure of IRAK4 from Biortusmonomer165-458
8CG;EDO;SO4;
Assess
Crystal structure of IRAK4 in complex with compound 30monomer165-458
8CG;
Assess
IRAK4 in complex with inhibitormonomer165-458
B8I;
Assess
Discovery of IRAK4 Inhibitors BAY1834845 and BAY1830839monomer165-458
R6R;
Assess
IRAK4 IN COMPLEX WITH inhibitormonomer165-458
CKN;
Assess
Crystal Structure of IRAK-4monomer165-458
T20;
Assess
IRAK4 in complex with inhibitormonomer165-458
B7R;
Assess
IRAK4 IN COMPLEX WITH inhibitormonomer165-458
SO4;K1H;
Assess
IRAK4 IN COMPLEX WITH inhibitormonomer165-458
NB5;
Assess
Crystal structure of IRAK4 in complex with compound 12monomer165-458
8C1;
Assess
IRAK4 IN COMPLEX WITH inhibitormonomer165-458
K1E;
Assess
Crystal structure of IRAK4 in complex with compound 11monomer165-458
8BY;
Assess
IRAK4 in complex with Compound 28monomer165-458
6R1;
Assess
Irak4-inhibitor co-structuremonomer192-459
Assess

2 SWISS-MODEL models

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
8dks.1.Amonomer0.84165-459
SO9;100.00
Assess
2a9i.1.Amonomer0.823-107
86.73
Assess